Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMX168L)

Drug Name
PLX2853 Drug Info
Indication
Disease Entry ICD 11 Status REF
Acute myeloid leukaemia 2A60 Phase 1/2 [1]
Solid tumour/cancer 2A00-2F9Z Phase 1/2 [1]
Cross-matching ID
TTD Drug ID
DMX168L

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Patented Agent(s)
Download the Complete Related Drug List
Drug(s) Targeting Bromodomain-containing protein 4 (BRD4)
Drug Name Drug ID Indication ICD 11 Highest Status REF
CPI-0610 DMPXOYJ Myelofibrosis 2A20.2 Phase 3 [3]
OTX-015 DMI8RG1 Acute myeloid leukaemia 2A60 Phase 1/2 [3]
RVX-208 DM1LO8K Alzheimer disease 8A20 Phase 1/2 [3]
INCB57643 DMBGU7V Advanced malignancy 2A00-2F9Z Phase 1/2 [2]
ABBV-744 DMTEA9C Acute myeloid leukaemia 2A60 Phase 1 [2]
(+)-JQ1 DM1CZSJ Testicular cancer 2C80 Phase 1 [4]
GSK525762 DMPAWBN Haematological malignancy 2B33.Y Phase 1 [3]
TEN010 DM4UOY5 Advanced solid tumour 2A00-2F9Z Phase 1 [3]
AZD5153 DMW4GM2 Solid tumour/cancer 2A00-2F9Z Phase 1 [2]
PMID26924192-Compound-104 DM346EU N. A. N. A. Patented [5]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Bromodomain-containing protein 4 (BRD4) TTRA6BO BRD4_HUMAN Inhibitor [2]

References

1 ClinicalTrials.gov (NCT04493619) PLX2853 as a Single Agent in Advanced Gynecological Malignancies and in Combination With Carboplatin in Platinum-Resistant Epithelial Ovarian Cancer. U.S. National Institutes of Health.
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 Targeting bromodomains: epigenetic readers of lysine acetylation.Nat Rev Drug Discov.2014 May;13(5):337-56.
4 Selective inhibition of BET bromodomains. Nature. 2010 Dec 23;468(7327):1067-73.
5 BET inhibitors in cancer therapeutics: a patent review.Expert Opin Ther Pat. 2016;26(4):505-22.